Semaglutide

Product Specifications

CAS: 910463-68-2

Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 diacid-γGlu-OEG-OEG linker)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉

Molecular Weight: 4113.58 Da

Purity: 99%+ (verified by HPLC)

Appearance: White to off-white lyophilized powder

Form: Lyophilized (freeze-dried)

Classification: GLP-1 Receptor Agonist (Glucagon-like Peptide-1 Analogue)

Half-life: Approximately 7 days (albumin-binding fatty acid modification at K26)

Storage

Semaglutide vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted semaglutide should be kept at -20°C for long-term storage or 2-8°C for short-term use. Does semaglutide expire? Once reconstituted with bacteriostatic water, semaglutide should be stored at 2-8°C and used within 28-30 days for optimal peptide stability. Do not freeze reconstituted solutions.

Solubility

Semaglutide is soluble in bacteriostatic water and sterile saline. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

Semaglutide is intended for research purposes only and is not approved for human use.

How Does Semaglutide Work? GLP-1 Receptor Mechanism of Action

• Semaglutide is a modified GLP-1 receptor agonist with two structural differences from native GLP-1: a substitution at position 8 (alanine replaced by alpha-aminoisobutyric acid) that confers resistance to DPP-4 enzymatic degradation, and a C18 fatty diacid chain at K26 via a hydrophilic spacer that enables reversible albumin binding and extends half-life to approximately 168 hours (7 days).
• GLP-1 receptors are expressed across multiple organ systems including pancreatic beta cells, the gastrointestinal tract, the cardiovascular system, and the central nervous system. Semaglutide activates these receptors to suppress glucagon secretion, slow gastric emptying, stimulate glucose-dependent insulin release, and reduce net energy intake through appetite signaling pathways.
• Semaglutide's central appetite suppression mechanism involves activation of GLP-1 receptors in the arcuate nucleus of the hypothalamus and the nucleus tractus solitarius of the brainstem, regions that regulate satiety signaling and energy homeostasis. Research in rodent models confirms that central GLP-1 receptor activation is both necessary and sufficient to produce the body weight reduction associated with GLP-1 agonism.
• Semaglutide side effects in preclinical models are consistent with GLP-1 receptor activation across multiple organ systems, primarily gastrointestinal effects including reduced food intake and nausea at higher doses, which are dose-dependent and typically attenuate with gradual dose escalation protocols.

Semaglutide Weight Loss Research: Body Composition and Appetite Suppression

• Semaglutide for weight loss is the most extensively studied application of this compound. Research in rodent obesity models demonstrates that GLP-1 receptor agonism reduces body weight through reduced energy intake via appetite suppression and delayed gastric emptying, which slows nutrient absorption and prolongs postprandial satiety signals.
• Semaglutide weight loss dosage chart data from preclinical studies shows clear dose-dependent responses across weekly administration protocols, with measurable body weight reductions beginning at low doses in mouse models and maximum effects at higher doses. Weekly dosing produces sustained receptor activation consistent with the compound's pharmacokinetic profile.
• Semaglutide before and after body composition analyses in preclinical obesity models demonstrate statistically significant reductions in total fat mass over 4-12 week research periods, with lean mass largely preserved, distinguishing GLP-1 agonist-driven weight loss from pure caloric restriction models where lean mass loss is more pronounced.
• Research on compounded semaglutide and generic semaglutide peptides highlights the critical role of structural integrity and purity. Peptide purity verified by HPLC and COA documentation ensures researchers are working with intact, bioactive compound capable of reproducing published receptor binding and pharmacodynamic findings.

Semaglutide vs Tirzepatide: GLP-1 and Dual Agonist Mechanism Comparison

• Semaglutide vs tirzepatide is the central mechanistic comparison in current incretin peptide research. Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist that simultaneously activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor via a single unimolecular peptide.
• The difference between semaglutide and tirzepatide in preclinical research models shows that dual receptor activation produces greater reductions in body weight and fat mass than GLP-1 agonism alone. GIPR activation on adipocytes and in the central nervous system contributes additional lipolytic and anorectic effects beyond what the GLP-1 pathway achieves independently.
• Tirzepatide vs semaglutide for weight loss in animal models consistently shows tirzepatide producing greater absolute body weight reduction at matched doses. Semaglutide offers a more extensively characterized research and pharmacological profile with a larger body of published data across multiple organ systems and model organisms.
• Switching from semaglutide to tirzepatide in research protocols requires accounting for the different receptor targets, different half-lives (semaglutide approximately 7 days, tirzepatide approximately 5 days), and distinct dose-response relationships. The difference between tirzepatide and semaglutide in potency means direct dose-for-dose comparisons require calibration across published literature.

Semaglutide Dosage for Research

Semaglutide dosing in preclinical research is structured around the compound's approximately 7-day half-life, with once-weekly or twice-weekly subcutaneous administration common in published metabolic and obesity protocols. Semaglutide dosage in animal model research includes:

• Subcutaneous injection (rodent models): 3 nmol/kg to 30 nmol/kg (approximately 12-124 mcg/kg) body weight, administered once weekly. This range covers the dose-response curve from threshold to near-maximal effect in published mouse obesity studies.
• Dose escalation protocols: Research commonly begins at the low end of the dosing range and escalates over 2-4 weeks to minimize gastrointestinal effects and improve tolerability at the model level, mirroring standard preclinical titration methodology.
• Semaglutide for weight loss in non-diabetic models: Dose-response studies in diet-induced obesity models show body weight reduction across the studied dose range, with fat mass loss as the primary driver of total body weight change.

How long does it take for semaglutide to work in animal research depends on the endpoint: appetite suppression is typically observed within 1-2 days of the first administration, while statistically significant body composition changes require 4-12 weeks of sustained weekly dosing. How long does semaglutide stay in your system reflects its approximately 7-day half-life, meaning steady-state concentrations are reached after approximately 4-5 weekly doses.

Research Protocol Notes

Semaglutide is supplied as a lyophilized (freeze-dried) powder. For research use, the peptide must be reconstituted with bacteriostatic water or sterile saline. Introduce the solvent slowly down the inside wall of the vial and gently swirl to dissolve. Do not shake or vortex the solution. How to inject semaglutide in research protocols typically involves subcutaneous administration in the abdomen or dorsal flank, with semaglutide injection sites rotated between administrations to prevent localized tissue irritation. Reconstituted semaglutide should be stored at 2-8°C and used within 28-30 days. Unreconstituted semaglutide peptide should be kept at -20°C for long-term stability.